Expression of RASAL2 in hepatocellular carcinoma and the clinical significance.
10.11817/j.issn.1672-7347.2015.03.003
- Author:
Hong SHEN
1
;
Xiaoling WU
;
Yan ZHANG
;
Ganlu DENG
;
Junli MA
;
Yanling QU
;
Shan ZENG
Author Information
1. Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular;
genetics;
metabolism;
Carrier Proteins;
genetics;
metabolism;
Humans;
Liver Neoplasms;
genetics;
metabolism;
Neoplasm Recurrence, Local;
Prognosis
- From:
Journal of Central South University(Medical Sciences)
2015;40(3):250-255
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the expression of RA SAL2 in patients with hepatocellular carcinoma (HCC), and to investigate the association of RASAL2 expression with pathological characteristics and prognosis.
METHODS:Immunohistochemical SP method was used to detect the expression of RA SAL2 in 164 samples of HCC tissue and the adjacent tissue. Th e association of RA SAL2 expression with clinical features and prognosis was analyzed.
RESULTS:The expression of RASAL2 in adjacent tissue was significantly increased compared to that in HCC tissue (P<0.001). The expression level of RASAL2 was associated with the degree of differentiation, tumor TNM stage and vascular invasion (P<0.001), but not associated with the level of AFP, tumor size, or the number of nodules (P>0.05). The 5 years recurrence-free survival (RFS) in patients with low expression of RASLA2 was significantly reduced compared with that in patients with high expression of RASLA2 (P<0.001). Cox analysis showed that low expression of RASLA2 was the independent factor for recurrence and death in HCC patients after surgery (P<0.001).
CONCLUSION:Low expression of RRASAL2 is significantly associated with the poor prognosis of HCC, which is an independent factor for HCC prognosis.
